Dr Reddys out-licenses steroid DFD-06 to Encore Dermatology
New Delhi: Drug major Dr Reddy's Laboratories on Tuesday said it has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology.
The drug is intended to be used for the treatment of moderate to severe plaque psoriasis.
"Under the terms of the agreement, Encore will be responsible for the commercialisation of DFD-05 in the United States," Reddy's Laboratories said in a regulatory filing.
Promius Pharma, a wholly owned subsidiary of Dr Reddy's Laboratories, is eligible to receive certain pre and post commercialisation milestone payments of up to USD 32.5 million, followed by fixed royalty on net sales, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd